期刊
MOLECULAR PHARMACEUTICS
卷 20, 期 6, 页码 2864-2875出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.2c01013
关键词
mitomycin C; TRAIL; liposome; colon cancer; synergistic antitumor
In this study, a multifunctional liposome (MTLPs) was developed to co-deliver TRAIL and MMC for overcoming TRAIL-resistant tumors. MTLPs exhibited efficient cellular uptake and a strong killing effect against TRAIL-resistant tumor cells. In vivo assays showed that MTLPs achieved 97.8% tumor suppression via the synergistic effect of TRAIL and MMC while ensuring biosafety.
Although tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) constitutes a promising antitumor drug, tumor resistance to TRAIL has become a major obstacle in its clinical application. Mitomycin C (MMC) is an effective TRAIL resistant tumor sensitizer, which indicates a potential utility of combination therapy. However, the efficacy of this combination therapy is limited owing to its short half-life and the cumulative toxicity of MMC. To address these issues, we successfully developed a multifunctional liposome (MTLPs) with human TRAIL protein on the surface and MMC encapsulated in the internal aqueous phase to codeliver TRAIL and MMC. MTLPs are uniform spherical particles that exhibit efficient cellular uptake by HT-29 TRAIL resistant tumor cells, thereby inducing a stronger killing effect compared with control groups. In vivo assays revealed that MTLPs efficiently accumulated in tumors and safely achieved 97.8% tumor suppression via the synergistic effect of TRAIL and MMC in an HT-29 tumor xenograft model while ensuring biosafety. These results suggest that the liposomal codelivery of TRAIL and MMC provides a novel approach to overcome TRAIL-resistant tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据